Beam Therapeutics Stock Alpha and Beta Analysis
| BEAM Stock | USD 32.40 3.79 13.25% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Beam Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Beam Therapeutics over a specified time horizon. Remember, high Beam Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Beam Therapeutics' market risk premium analysis include:
Beta 0.32 | Alpha 0.37 | Risk 4.39 | Sharpe Ratio 0.11 | Expected Return 0.5 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Beam |
Beam Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Beam Therapeutics market risk premium is the additional return an investor will receive from holding Beam Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Beam Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Beam Therapeutics' performance over market.| α | 0.37 | β | 0.32 |
Beam Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Beam Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Beam Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Beam Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Beam Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Beam Therapeutics shares will generate the highest return on investment. By understating and applying Beam Therapeutics stock market price indicators, traders can identify Beam Therapeutics position entry and exit signals to maximize returns.
Beam Therapeutics Return and Market Media
The median price of Beam Therapeutics for the period between Tue, Nov 19, 2024 and Mon, Feb 17, 2025 is 26.57 with a coefficient of variation of 6.82. The daily time series for the period is distributed with a sample standard deviation of 1.82, arithmetic mean of 26.62, and mean deviation of 1.41. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Walsh Kathleen E of 16532 shares of Beam Therapeutics at 34.33 subject to Rule 16b-3 | 11/20/2024 |
2 | Insider Trading | 12/02/2024 |
3 | Beam Therapeutics Inc Announces Presentation of BEAM-101 Data at 2025 Tandem Meetings | 01/23/2025 |
4 | Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference | 01/30/2025 |
5 | Investors in Beam Therapeutics from three years ago are still down 55, even after 3.8 percent gain this past week | 01/31/2025 |
6 | John M. Evans Sells 30,000 Shares of Beam Therapeutics Inc. Stock | 02/05/2025 |
7 | Lilly reports full Q4 2024 financial results and provides 2025 guidance | 02/06/2025 |
8 | Is Beam Therapeutics Outperforming Other Medical Stocks This Year | 02/10/2025 |
9 | Wall Street Analysts See a 67.27 percent Upside in Beam Therapeutics Can the Stock Really Move This High | 02/13/2025 |
10 | Beam Secures 11M Series A to Transform Construction Finance and Empower Contractors | 02/14/2025 |
About Beam Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Beam or other stocks. Alpha measures the amount that position in Beam Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Dividend Yield | 0.0119 | 0.0106 | Price To Sales Ratio | 6.39 | 6.07 |
Beam Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Beam Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Beam Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Beam Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Beam Therapeutics. Please utilize our Beneish M Score to check the likelihood of Beam Therapeutics' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Beam Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Beam Therapeutics Backtesting, Beam Therapeutics Valuation, Beam Therapeutics Correlation, Beam Therapeutics Hype Analysis, Beam Therapeutics Volatility, Beam Therapeutics History and analyze Beam Therapeutics Performance. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Beam Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.